Editorial: Antifolates in prevention of HIV-associated opportunistic infections and in intermittent preventive treatment of malaria in Africa

Tropical Medicine and International Health

Volumn 10, Issue 4, 2005, Pages 293-294

  Kobbe, Robin ^a   Marks, Florian ^a   May, Jürgen ^a   Meyer, Christian G ^a  

^a BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

Author keywords

Cross resistance; Folic acid antagonists; HIV; Intermittent preventive treatment; Malaria

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; ARTEMISIN; CHLOROQUINE; COTRIMOXAZOLE; FOLIC ACID ANTAGONIST; PYRIMETHAMINE; SULFADOXINE; SULFAMETHOXAZOLE; TRIMETHOPRIM;

AFRICA; AFRICA SOUTH OF THE SAHARA; ANTIBIOTIC PROPHYLAXIS; CROSS RESISTANCE; DRUG COST; DRUG DISTRIBUTION; DRUG MANUFACTURE; DRUG MECHANISM; ECONOMIC ASPECT; EDITORIAL; GHANA; HEALTH CARE POLICY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; INFECTION CONTROL; INTERMITTENT PREVENTIVE TREATMENT; LYMPHOCYTE COUNT; MALARIA; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; NATURAL SELECTION; OPPORTUNISTIC INFECTION; PLASMODIUM FALCIPARUM; PREVALENCE; PROPHYLAXIS; SELF MEDICATION; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; VIRUS LOAD; WORLD HEALTH ORGANIZATION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; DRUG RESISTANCE; FOLIC ACID ANTAGONISTS; HUMANS; MALARIA, FALCIPARUM;

HUMAN IMMUNODEFICIENCY VIRUS; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; PLASMODIUM FALCIPARUM;

EID: 17644427363     PISSN: 13602276     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2005.01400.x     Document Type: Editorial

References (9)

1. Chintu C, Bhat GJ, Walker AS et al. (2004) Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet 364, 1865-1871.
2. Iyer JK, Milhous WK, Cortese JF, Kublin JG & Plowe CV (2001) Plasmodium falciparum cross-resistance between trimethoprim and pyrimethamine. Lancet 358, 1066-1067.
3. Khalil I, Ronn AM, Alifrangis M, Gabar HA, Satti GM & Bygbjerg IC (2003) Dihydrofolate reductase and dihydropteroate synthase genotypes associated with in vitro resistance of Plasmodium falciparum to pyrimethamine, trimethoprim, sulfadoxine, and sulfamethoxazole. American Journal of Tropical Medicine and Hygiene 68, 586-589.
4. Marks F, Evans J, Meyer CG et al. (2005) High prevalence of markers for sulfadoxine and pyrimethamine resistance of Plasmodium falciparum in the absence of drug pressure in the Ashanti Region of Ghana. Antimicrobial Agents and Chemotherapy 2005; 49, 1101-1105.
5. Mermin J, Lule J, Ekwaru JP et al. (2004) Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 364, 1428-1434.
6. Schellenberg D, Menendez C, Kahigwa E et al. (2001) Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet 357, 1471-1477.
7. UNAIDS/WHO (2000). Provisional WHO/UNAIDS recommedations on the use of cotrimoxazole prophylaxis in adults and children living with HIV/AIDS in Africa. http://www. unaids.org/html/pub/publications/irc-pub04/recommendation_en_pdf. htm
8. UNAIDS/WHO (2004). Joint WHO/UNAIDS/UNICEF statement on use of cotrimoxazole as prophylaxis in HIV exposed and HIV infected children. http://www.unaids.org/html/pub/media/press-statements01/ ps_cotrimoxazole_22nov04_en_pdf.htm
9. WHO/UNICEF (2003). The Africa Malaria Report 2003. Geneva World Health Organization, 31-37.